Edwards Lifesciences Corp (EW) : March Altus Capital Management Lp reduced its stake in Edwards Lifesciences Corp by 54.48% during the most recent quarter end. The investment management company now holds a total of 17,443 shares of Edwards Lifesciences Corp which is valued at $1.8 Million after selling 20,879 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on May 12, 2016.Edwards Lifesciences Corp makes up approximately 18.09% of March Altus Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Her Majesty The Queen In Right Of The Province Of Alberta… reduced its stake in EW by selling 42,300 shares or 18.39% in the most recent quarter. The Hedge Fund company now holds 187,700 shares of EW which is valued at $19.3 Million. Edwards Lifesciences Corp makes up approx 0.29% of Her Majesty The Queen In Right Of The Province Of Alberta…’s portfolio.Winslow Capital Management reduced its stake in EW by selling 1,101,493 shares or 30.97% in the most recent quarter. The Hedge Fund company now holds 2,454,726 shares of EW which is valued at $252.8 Million. Edwards Lifesciences Corp makes up approx 0.99% of Winslow Capital Management’s portfolio. Braun Stacey Associates Inc added EW to its portfolio by purchasing 102,625 company shares during the most recent quarter which is valued at $10.9 Million. Edwards Lifesciences Corp makes up approx 0.70% of Braun Stacey Associates Inc’s portfolio.Pitcairn Co boosted its stake in EW in the latest quarter, The investment management firm added 371 additional shares and now holds a total of 7,333 shares of Edwards Lifesciences Corp which is valued at $778,838. Edwards Lifesciences Corp makes up approx 0.10% of Pitcairn Co’s portfolio.Hall Laurie J Trustee reduced its stake in EW by selling 50 shares or 1.62% in the most recent quarter. The Hedge Fund company now holds 3,030 shares of EW which is valued at $321,816. Edwards Lifesciences Corp makes up approx 0.19% of Hall Laurie J Trustee’s portfolio.
Edwards Lifesciences Corp opened for trading at $99.12 and hit $100.5 on the upside on Friday, eventually ending the session at $99.11, with a gain of 1.32% or 1.29 points. The heightened volatility saw the trading volume jump to 26,26,409 shares. Company has a market cap of $20,988 M.
On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $110 .Company shares were Reiterated by Canaccord Genuity on Apr 27, 2016 to “Buy”, Firm has raised the Price Target to $ 123 from a previous price target of $113 .Company shares were Reiterated by Leerink Partners on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $93 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.